Results 181 to 190 of about 361,864 (351)

Epidermal Interferon kappa drives cutaneous lupus‐like lesions, photosensitivity and systemic autoimmunity in vivo

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Keratinocyte‐derived interferon kappa (IFN‐κ) is chronically overexpressed in human non‐lesional systemic lupus erythematosus (SLE) skin. Recent evidence suggests that epidermal signals instruct the immune system in SLE, but whether epidermal IFN‐κ alone is sufficient to drive lupus phenotypes has not been investigated.
Benjamin Klein   +14 more
wiley   +1 more source

ROS‐induced modifications of fibrin clots connect immune responses to atherothrombosis in systemic lupus erythematosus

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Cardiovascular events are major determinants of morbidity and mortality in systemic lupus erythematosus (SLE), particularly in patients with renal involvement. While oxidative stress has been implicated in driving vascular and renal damage in SLE, the specific mechanisms remain unclear.
Matteo Becatti   +13 more
wiley   +1 more source

Cytokine pathways driving diverse tissue pathologies in rheumatoid arthritis

open access: yesArthritis &Rheumatology, Accepted Article.
Rheumatoid arthritis is a complex systemic disorder characterised primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease e.g. of the lung with potentially devastating clinical consequences.
Aurelie Najm   +2 more
wiley   +1 more source

A randomized, placebo‐controlled trial of hydroxychloroquine in incomplete lupus

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity and incidence of SLE. Methods Hydroxychloroquine (HCQ) was chosen as an
Nancy J. Olsen   +14 more
wiley   +1 more source

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell‐Targeted Therapies

open access: yesArthritis &Rheumatology, Accepted Article.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no FDA‐approved disease‐modifying therapies for SjD.
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

National Mortality Databases to Assess Disease Burden in Systemic Autoimmune Diseases: A Valuable Resource, But with Limitations

open access: yesArthritis &Rheumatology, Accepted Article.
Disease‐specific mortality statistics are useful measures of disease burden. Population‐based studies from a few United States counties have reported mortality in systemic autoimmune diseases (SAID). However, due to substantial differences in the population structure of these counties as well as relatively small numbers of SAID deaths in these counties,
Ram Raj Singh
wiley   +1 more source

Home - About - Disclaimer - Privacy